RÉSUMÉ
The significance of glomerular IgM deposit intensity in IgA Nephropathy (IgAN) remained ambiguous and requires further research. Patients with biopsy-proven IgAN in our hospital from January 2018 to May 2023 were recruited into this retrospective single-center study. Patients who presented with positive IgM deposit were included in IgM + cohort while patients with negative IgM deposit were included in IgM- cohort. Of the IgM+, patients whose IF intensity of IgM deposits exceeded 1+ formed IgM-H cohort while patients whose IF intensity of IgM deposits was equal to 1+ consisted IgM-L cohort. Pairwise comparisons were performed among these cohorts to determine clinical disparities, following the propensity score matching process. Among 982 IgAN patients, 539 patients presented with positive IgM deposit. The Kaplan-Meier analysis showed that the IgM deposit did not contribute adversely to the outcomes (eGFR decreased from the baseline ≥ 50% continuously or reached end-stage renal disease). However, the Cox regression analysis showed that increased intensity of IgM deposit was an independent risk factor (p = 0.03) in IgM+. The IgM-H exhibited more pronounced segmental glomerulosclerosis (p = 0.02) than the IgM-L, which may also be associated more directly with higher urine protein levels (p = 0.02). Moreover, our generalized linear mixed model demonstrated a remarkably higher urine albumin/creatinine ratio (p < 0.01) and serum creatinine (p = 0.04) levels as well as lower serum albumin (p < 0.01) level in IgM-H persistently during the 5-year follow-up. This study concluded that increased intensity of glomerular IgM deposits may contribute adversely to clinicopathologic presentation and outcome in those IgM + patients.
Sujet(s)
Débit de filtration glomérulaire , Glomérulonéphrite à dépôts d'IgA , Immunoglobuline M , Glomérule rénal , Humains , Immunoglobuline M/sang , Mâle , Glomérulonéphrite à dépôts d'IgA/immunologie , Femelle , Études rétrospectives , Adulte , Études de suivi , Glomérule rénal/anatomopathologie , Glomérule rénal/immunologie , Adulte d'âge moyen , Facteurs de risque , Défaillance rénale chronique/étiologie , Défaillance rénale chronique/immunologie , Estimation de Kaplan-Meier , Évolution de la maladie , Biopsie , Pertinence cliniqueRÉSUMÉ
BACKGROUND: Since March 2020, COVID-19 has evolved from a localized outbreak to a global pandemic. We assessed the seroprevalence of COVID-19 in three towns in the Centre Sud region of Burkina Faso. METHODS: A population-based cross-sectional survey was conducted in three middle-sized cities in Burkina Faso's Centre Sud region, from June to July 2021. Subjects aged 16 or over at the time of the survey were considered for this seroprevalence study. The Biosynex COVID-19 BSS rapid test was used to detect immunoglobulin G (IgG) and immunoglobulin M (IgM) against SARS-CoV-2. A standardized questionnaire was also administered to collect additional information. RESULTS: A total of 2449 eligible participants (age ≥ 16 years) were identified. Serological tests for COVID-19 were performed in 2155 individuals, of which 2143 valid tests were retained and analyzed. Out of the entire sample, 246 positive tests were observed, corresponding to a prevalence of 11.48%. Prevalence was 9.35% (58 cases) in Kombissiri, 12.86% (80 cases) in Manga and 11.99% (108 cases) in Pô. By gender, 13.37% of women (164 cases) tested positive, and 8.95% of men (82 cases). Women accounted for 66.67% of all positive test subjects. The results from the multivariate analysis show a significantly higher seroprevalence in women (p = 0.007), people over 55 years old (p = 0.004), overweight people (p = 0.026) and those with drinking water sources at home (p = 0.013). CONCLUSIONS: The results of this study show that the COVID-19 virus also circulates in the population of middle-sized cities in Burkina Faso, far more than officially reported by the information service of the government of Burkina Faso, given the lack of systematic testing in the general population in the country. The study also highlighted the greater vulnerability of women, older and overweight individuals to the epidemic. The preventive measures put in place to fight the pandemic must take these different factors into account.
Sujet(s)
COVID-19 , Villes , SARS-CoV-2 , Humains , COVID-19/épidémiologie , COVID-19/sang , Burkina/épidémiologie , Femelle , Mâle , Adulte , Études séroépidémiologiques , Études transversales , Adulte d'âge moyen , Facteurs de risque , Adolescent , SARS-CoV-2/immunologie , SARS-CoV-2/isolement et purification , Villes/épidémiologie , Jeune adulte , Immunoglobuline G/sang , Sujet âgé , Anticorps antiviraux/sang , Immunoglobuline M/sangRÉSUMÉ
Hepatitis Delta Virus (HDV), a satellite virus of Hepatitis B virus, exacerbates liver damage in affected individuals. Screening for HDV antibodies in HBsAg positive patients is recommended, but the diagnostic accuracy of serological tests remains uncertain. This review aimed to assess the diagnostic accuracy of serological tests for HDV. We searched PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Scopus etc. for relevant studies. Studies measuring the sensitivity and specificity of serological HDV tests against PCR as a reference standard were included. Pooled sensitivity and specificity for each test method and sero-marker were calculated. The review included six studies with 11 study arms, evaluating ARCHITECT immunoassay, EIA, ELISA, QMAC, RIA, and Western Blot test methods targeting Anti-HDV IgG, Total anti-HDV and Anti-HDV IgM. Sensitivities for Anti-HDV IgG, Total Anti-HDV and Anti-HDV IgM, tests were 97.4%, 51.9%, and 62.0%, respectively, with specificities of 95.3%, 80.0%, and 85.0%. Our findings, with its limited number of studies, suggest that HDV serological tests, particularly those identifying Anti IgG exhibit high accuracy and can serve as effective screening tools for HDV.
Sujet(s)
Hépatite D , Virus de l'hépatite delta , Sensibilité et spécificité , Tests sérologiques , Humains , Virus de l'hépatite delta/immunologie , Hépatite D/diagnostic , Hépatite D/virologie , Hépatite D/sang , Hépatite D/immunologie , Tests sérologiques/méthodes , Tests sérologiques/normes , Immunoglobuline G/sang , Anticorps de l'hépatite/sang , Immunoglobuline M/sangRÉSUMÉ
Cite this article as: Balaban YH, Ismail M, Nur Ayar S. Selective immunoglobulin M deficiency in patients with autoimmune liver diseases. Turk J Gastroenterol. 2024;35(6):505-508.
Sujet(s)
Immunoglobuline M , Humains , Immunoglobuline M/sang , Immunoglobuline M/déficit , Femelle , Mâle , Maladies auto-immunes/immunologie , Maladies auto-immunes/complications , Maladies du foie/immunologie , Maladies du foie/étiologie , Adulte d'âge moyen , Hépatite auto-immune/complications , Hépatite auto-immune/immunologie , AdulteRÉSUMÉ
Background: Production of anti-phosphatidylserine (anti-PS) antibodies has been associated with malaria and can aggravate pathology. How these autoantibodies develop during early childhood in a malaria context is not known. We examined levels of anti-PS IgG and IgM antibodies in a longitudinal cohort of mother-baby pairs during birth, in the infants at 2.5, 6 months, and in mothers and their babies at 9 months postpartum. Results: There was no difference between levels of anti-PS IgG in cord blood and the mothers' peripheral blood at birth. However, anti-PS IgM levels were significantly higher in the mothers compared to the infants' cord blood, and IgM levels were steadily increasing during the first 9 months of the infants' life. In infants that had the highest anti-PS IgM levels at birth, there was a decline until 6 months with a rise at 9 months. Infants that possessed high anti-PS IgG at birth also exhibited a progressive decline in levels. When anti-PS were correlated to different fractions of B-cells, there were several correlations with P. falciparum specific atypical B cells both at birth and at 2.5 months for the infants, especially for anti-PS IgM. Anti-PS also correlated strongly to C1q-fixing antibodies at birth. Conclusion: These results show that anti-PS IgG acquired by mothers could be transferred transplacentally and that IgM antibodies targeting PS are acquired during the first year of life. These results have increased the knowledge about autoimmune responses associated with infections in early life and is critical for a comprehensive understanding of malaria vaccine functionality in endemic areas.
Sujet(s)
Immunoglobuline G , Immunoglobuline M , Phosphatidylsérine , Humains , Immunoglobuline M/sang , Immunoglobuline M/immunologie , Immunoglobuline G/sang , Immunoglobuline G/immunologie , Femelle , Phosphatidylsérine/immunologie , Nourrisson , Ouganda , Nouveau-né , Adulte , Plasmodium falciparum/immunologie , Mâle , Paludisme à Plasmodium falciparum/immunologie , Paludisme à Plasmodium falciparum/parasitologie , Paludisme à Plasmodium falciparum/épidémiologie , Immunité acquise d'origine maternelle , Autoanticorps/immunologie , Autoanticorps/sang , Anticorps antiprotozoaires/immunologie , Anticorps antiprotozoaires/sang , Mères , Sang foetal/immunologie , Lymphocytes B/immunologie , Études longitudinalesRÉSUMÉ
OBJECTIVE: The study aimed to characterize serum immunoglobulin (Ig) concentrations and their relationship with clinical and paraclinical features in patients with COPD group E in the stable stage. Additionally, the study focused on evaluating the relationship between serum Ig levels and the risk of exacerbations over the next 12 months, thereby clarifying the role of serum Ig deficiency in affecting the future risk for these patients. METHODS: A prospective observational study assessed IgG, IgA, IgM, and IgE levels in 67 COPD patients and 30 healthy controls at Military Hospital 103 from October 2017 to August 2020. Primary outcomes included Ig isotype levels in COPD patients, with secondary outcomes exploring differences compared to controls and associations with clinical variables. RESULTS: COPD patients showed significantly lower IgG concentrations and higher IgA levels than controls. IgM and IgE levels did not differ significantly. Subgroup analysis revealed notable decreases in IgG1 and IgG3 concentrations, with 10.4% of patients exhibiting reduced IgG levels and 0.3% diagnosed with common variable immunodeficiency. No significant associations were found between Ig levels and exacerbation risk or clinical variables. CONCLUSIONS: Serum IgG and IgM concentrations were significantly reduced in COPD patients compared to normal individuals, with IgG1 and IgG3 concentrations notably low. Serum IgA levels were significantly higher in COPD patients compared with normal controls. However, no significant association was found between Ig concentrations, particularly serum IgG deficiency and its subclasses, with the frequency and risk of exacerbations during 12 months of longitudinal follow-up. Caution is warranted in the use of immunoglobulin therapy in the treatment of COPD patients. TRIAL REGISTRATION: An independent ethics committee approved the study (Ethics Committee of Military Hospital 103 (No. 57/2014/VMMU-IRB), which was performed in accordance with the Declaration of Helsinki, Guidelines for Good Clinical Practice.
Sujet(s)
Broncho-pneumopathie chronique obstructive , Humains , Broncho-pneumopathie chronique obstructive/sang , Broncho-pneumopathie chronique obstructive/immunologie , Broncho-pneumopathie chronique obstructive/thérapie , Mâle , Femelle , Études prospectives , Sujet âgé , Adulte d'âge moyen , Immunoglobuline G/sang , Études cas-témoins , Immunoglobuline A/sang , Évolution de la maladie , Immunoglobulines/sang , Immunoglobuline M/sangRÉSUMÉ
BACKGROUND: Modified 2-tiered testing (MTTT) for Lyme disease utilizes automatable, high throughput immunoassays (AHTIs) in both tiers without involving western immunoblots, offering performance and practical advantages over standard 2-tiered testing (STTT; first-tier AHTI followed by immunoglobulin M (IgM) and immunoglobulin G (IgG) western immunoblots). For MTTT, Centers for Disease Control and Prevention recommends using AHTI test kits that have been cleared by Food and Drug Administration (FDA) specifically for this intended use. We evaluated performance of FDA-cleared MTTT commercial test kits from 3 manufacturers by comparing with STTT results. METHODS: We performed MTTT (total antibody AHTI with reflex to separate IgM and IgG AHTIs) using test kits from Diasorin, Gold Standard Diagnostics (GSD), and Zeus Scientific on 382 excess serum samples submitted to the clinical laboratory for routine Lyme disease serologic testing in July 2018, measuring agreement between MTTT and STTT using the κ statistic. RESULTS: Overall agreement with STTT was 0.87 (95% confidence interval [CI], .77-.97) using Diasorin assays (almost perfect agreement), 0.80 (95% CI, .68-.93) using GSD assays (substantial agreement) and 0.79 (95% CI, .68-.90) using Zeus assays (substantial agreement). For detection of IgM reactivity, agreement between MTTT and STTT was 0.70 (.51-.90; substantial), 0.63 (95% CI, .44-.82; substantial) and 0.56 (95% CI, .38-.73; moderate), respectively. For detection of IgG reactivity, MTTT/STTT agreement was 0.73 (95% CI,.58-.88), 0.78 (95% CI, .62-.94), and 0.75 (95% CI, .60-.90), respectively (substantial agreement in all cases). CONCLUSIONS: MTTT results obtained using commercial test kits from 3 different manufacturers had substantial to almost perfect agreement with STTT results overall and moderate to substantial agreement for IgM and IgG detection independently. Commercial MTTT tests can be used broadly for the diagnosis of Lyme disease.
Sujet(s)
Anticorps antibactériens , Immunoglobuline G , Immunoglobuline M , Maladie de Lyme , Trousses de réactifs pour diagnostic , Tests sérologiques , Maladie de Lyme/diagnostic , Maladie de Lyme/immunologie , Maladie de Lyme/sang , Humains , Tests sérologiques/méthodes , Immunoglobuline G/sang , Immunoglobuline M/sang , Trousses de réactifs pour diagnostic/normes , Anticorps antibactériens/sang , Algorithmes , Sensibilité et spécificité , Dosage immunologique/méthodes , États-Unis , Borrelia burgdorferi/immunologie , Adulte d'âge moyen , Adulte , FemelleRÉSUMÉ
We evaluated the diagnostic performance of newly developed microfluidic microplate-based fluorescent ELISA for anti-SARS-CoV-2 antibody detection: the Veri-Q opti COVID-19 IgG and IgM ELISAs (hereafter, "Opti IgG/M"; MiCo BioMed, Gyeonggi-do, Republic of Korea), in comparison with conventional ELISAs. A total of 270 serum samples were analyzed, among which 90 samples were serially obtained from 25 COVID-19 patients. Another 180 samples were collected from 180 SARS-CoV-2-negative individuals. As comparative assays, we used SCoV-2 Detect IgG/M ELISA (hereafter, "InBios IgG/M"; InBios, Seattle, WA, USA) and Veri-Q COVID-19 IgG/IgM ELISA (hereafter, "Veri-Q IgG/M"; MiCo BioMed). Compared with conventional ELISAs, the Opti IgG yielded 97.1-100.0% positive percent agreement, 95.2-98.0% negative percent agreement, 96.3-97.8% total percent agreement, and kappa values of 0.90-0.94. Between the Opti IgM and the InBios IgM, the values were 93.7%, 96.6%, 95.9%, and 0.89, respectively. For the Opti IgG, sensitivities for the samples collected from 0-7, 8-14, 15-21, and ≥ 22 days after symptom onset were 40.0, 58.3, 94.1, and 100.0%, respectively. The values for the Opti IgM were 30.0, 54.2, 88.2, and 80%, respectively. The diagnostic specificities of the Opti IgG and IgM were 99.4 and 97.2%, respectively. The microfluidic microplate-based fluorescent ELISAs showed comparable diagnostic performance to conventional ELISAs for detecting anti-SARS-CoV-2 antibodies. With the combination of high throughput, a simplified workflow, and the ability to analyze reduced volumes, this new technology has great potential for improving SARS-CoV-2 serologic testing.
Sujet(s)
Anticorps antiviraux , Dépistage sérologique de la COVID-19 , COVID-19 , Test ELISA , Immunoglobuline G , Immunoglobuline M , SARS-CoV-2 , Humains , Immunoglobuline M/sang , Immunoglobuline M/immunologie , Immunoglobuline G/sang , SARS-CoV-2/immunologie , SARS-CoV-2/isolement et purification , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , COVID-19/diagnostic , COVID-19/sang , Test ELISA/méthodes , Dépistage sérologique de la COVID-19/méthodes , Sensibilité et spécificité , Microfluidique/méthodes , Microfluidique/instrumentation , Adulte d'âge moyen , Femelle , Mâle , Sujet âgéRÉSUMÉ
BACKGROUND: Toxoplasmosis is a zoonotic parasitic disease caused by Toxoplasma gondii (T. gondii). It has a wide host range and is capable of vertical transmission in pregnant women, which may lead to undesirable pregnancy outcomes such as congenital malformations, miscarriage, premature birth and stillbirth. This study investigated the seroprevalence of T. gondii infection among pregnant women attending the antenatal clinic at Namwala District Hospital in Southern Zambia. METHODS: This was a cross-sectional study where blood was collected, and the serum was tested for Toxoplasma IgG and IgM. A questionnaire was administered to participants on demographic characteristics and risk factors. Data were entered in Microsoft Excel and exported to STATA version 14 for analysis. RESULTS: A total of 401 women were enrolled in the study from 3 March to 5 August 2021. The seroprevalence of Toxoplasma IgG was 4.2% (n=17), while the seroprevalence of Toxoplasma IgM was 0.7% (n=3). The median age was 27 (IQR: 24-30) years, and a larger proportion had primary-level education (n=223, 55.6%). The majority (81.6%) of the women were married. None of the risk factors investigated in this study were significant for T. gondii infection. CONCLUSION: There was a low seroprevalence of T. gondii infection among pregnant women in the Namwala district of Southern Province, Zambia, and regular screening may not be warranted in this population. Continued research on toxoplasmosis is recommended to understand its epidemiology across Zambia.
Sujet(s)
Anticorps antiprotozoaires , Immunoglobuline M , Complications parasitaires de la grossesse , Toxoplasma , Toxoplasmose , Humains , Femelle , Zambie/épidémiologie , Études transversales , Études séroépidémiologiques , Adulte , Grossesse , Toxoplasmose/épidémiologie , Toxoplasmose/sang , Facteurs de risque , Toxoplasma/immunologie , Jeune adulte , Immunoglobuline M/sang , Anticorps antiprotozoaires/sang , Complications parasitaires de la grossesse/épidémiologie , Complications parasitaires de la grossesse/sang , Immunoglobuline G/sang , Prise en charge prénataleRÉSUMÉ
Introduction: Coronavirus Disease 2019 (COVID-19) is a severe respiratory illness caused by the RNA virus SARS-CoV-2. Globally, there have been over 759.4 million cases and 6.74 million deaths, while Ecuador has reported more than 1.06 million cases and 35.9 thousand deaths. To describe the COVID-19 pandemic impact and the vaccinations effectiveness in a low-income country like Ecuador, we aim to assess the seroprevalence of IgG and IgM antibodies against SARS-CoV-2 in a sample from healthy blood donors at the Cruz Roja Ecuatoriana. Methods: The present seroprevalence study used a lateral flow immunoassay (LFIA) to detect anti-SARS-CoV-2 IgG and IgM antibodies in months with the highest confirmed case rates (May 2020; January, April 2021; January, February, June, July 2022) and months with the highest vaccination rates (May, June, July, August, December 2021) in Quito, Ecuador. The IgG and IgM seroprevalence were also assessed based on sex, age range, blood type and RhD antigen type. The sample size was 8,159, and sampling was performed based on the availability of each blood type. Results: The results showed an overall IgG and IgM seroprevalence of 47.76% and 3.44%, respectively. There were no differences in IgG and IgM seroprevalences between blood groups and sex, whereas statistical differences were found based on months, age range groups, and RhD antigen type. For instance, the highest IgG seroprevalence was observed in February 2022 and within the 17-26 years age range group, while the highest IgM seroprevalence was in April 2021 and within the 47-56 years age range group. Lastly, only IgG seroprevalence was higher in RhD+ individuals while IgM seroprevalence was similar across RhD types. Discussion: This project contributes to limited data on IgG and IgM antibodies against SARS-CoV-2 in Ecuador. It suggests that herd immunity may have been achieved in the last evaluated months, and highlights a potential link between the RhD antigen type and COVID-19 susceptibility. These findings have implications for public health strategies and vaccine distribution not only in Ecuador but also in regions with similar characteristics.
Sujet(s)
Anticorps antiviraux , Donneurs de sang , COVID-19 , Immunoglobuline G , Immunoglobuline M , SARS-CoV-2 , Humains , COVID-19/épidémiologie , COVID-19/immunologie , Équateur/épidémiologie , Immunoglobuline G/sang , Études séroépidémiologiques , Immunoglobuline M/sang , Mâle , SARS-CoV-2/immunologie , Adulte , Donneurs de sang/statistiques et données numériques , Anticorps antiviraux/sang , Femelle , Adulte d'âge moyen , Adolescent , Jeune adulte , Sujet âgé , PandémiesRÉSUMÉ
A woman in her 40s known to have systemic lupus erythematosus presented with a maculopapular rash on her face, neck and chest following measles exposure. She had received a single-dose measles vaccine as a child in the 1970s and was therefore presumed to be immune, and thus not infectious. As a result, she was initially managed in an open bay. Measles virus IgM antibody in serum was undetectable; however, measles virus RNA was subsequently detected in throat swab by PCR, which is consistent with current infection. Measles is one of the most transmissible diseases in the world and cases are rising both in the UK and globally. Our case and literature review highlight the risk of vaccine failure in measles, especially in people who have not received two doses of the measles, mumps and rubella vaccine. It also highlights the challenges in diagnosing measles in previously vaccinated individuals.
Sujet(s)
Rougeole , Humains , Rougeole/prévention et contrôle , Rougeole/diagnostic , Femelle , Vaccin contre la rougeole , Adulte , Virus de la rougeole/immunologie , Virus de la rougeole/isolement et purification , Vaccin contre la rougeole, les oreillons et la rubéole , Lupus érythémateux disséminé/complications , Lupus érythémateux disséminé/immunologie , Vaccination , Adulte d'âge moyen , Anticorps antiviraux/sang , Immunoglobuline M/sangRÉSUMÉ
Introduction. In India, the SARS-CoV-2 Delta wave (2020-2021) faded away with the advent of the Omicron variants (2021-present). Dengue incidences were observed to be less in Southeast Asia during the active years of the pandemic (2020-2021). However, dengue virus type 3 (DV3) cases were increasingly reported in this region (including India) concurrent with the progression of the Omicron waves since 2022.Hypothesis. What could be the reason(s) behind this unusual DV3 surge after an overall dip in dengue incidences in many parts of Southeast Asia?Aim. We, therefore, investigated the current state of cross-reactivity of prevalent (Omicron era) SARS-CoV-2 serums with different DV serotypes and evaluated the impact of such serums on DV neutralization in cell culture.Methodology. Fifty-five COVID-19 serum samples (January-September 2022) and three pre-pandemic archived serum samples from apparently healthy individuals were tested for DV or SARS-CoV-2 IgM/IgG using the lateral flow immunoassays. DV1-4 virus neutralization tests (VNTs) were done with the SARS-CoV-2 antibody (Ab)-positive serums in Huh7 cells. DV3 envelope (env) gene was PCR amplified and sequenced for three archived DV isolates, one from 2017 and two from 2021.Results. SARS-CoV-2 Ab-positive samples constituted 74.5â% of the serums. Of these, 41.5â% were DV cross-reactive and 58.5â% were not. The DV cross-reactive serums neutralized all DV serotypes (DV1-4), as per previous results and this study. The DV non-cross-reactive serums (58.5â%) also cross-neutralized DV1, 2 and 4 but increased DV3 infectivity by means of antibody-dependent enhancement of infection as evident from significantly higher DV3 titres in VNT compared to control serums. The DV3 envelope was identical among the three isolates, including isolate 1 used in VNTs. Our results suggest that DV cross-reactivity of SARS-CoV-2 serums diminished with the shift from Delta to Omicron prevalence. Such COVID-19 serums (DV non-cross-reactive) might have played a major role in causing DV3 surge during the Omicron waves.Conclusion. Patients suspected of dengue or COVID-19 should be subjected to virus/antigen tests and serological tests for both the diseases for definitive diagnosis, prognosis and disease management.
Sujet(s)
Anticorps antiviraux , COVID-19 , Réactions croisées , Virus de la dengue , SARS-CoV-2 , Humains , SARS-CoV-2/immunologie , SARS-CoV-2/génétique , COVID-19/virologie , COVID-19/épidémiologie , COVID-19/sang , COVID-19/immunologie , Anticorps antiviraux/sang , Virus de la dengue/génétique , Virus de la dengue/immunologie , Virus de la dengue/classification , Inde/épidémiologie , Dengue/virologie , Dengue/sang , Dengue/épidémiologie , Dengue/immunologie , Tests de neutralisation , Anticorps neutralisants/sang , Anticorps neutralisants/immunologie , Immunoglobuline G/sang , Immunoglobuline M/sangRÉSUMÉ
INTRODUCTION: Since the Syrian Civil War began in 2011, the official number of refugees under temporary protection in Turkiye is reported to be 3,522,036 in 2023. Most of the Syrians living outside the refugee camps have worse conditions in terms of access to healthcare centers and social opportunities, compared to those living in camps. The Sanliurfa province hosts the third highest number of Syrians (370,291) in Turkiye. There are no data about the seroprevalence of Toxoplasma gondii (T. gondii), rubella (rub), or cytomegalovirus (CMV) among Syrian refugees in Sanliurfa. We aimed to investigate the seroprevalence of T. gondii, rub, and CMV infections among female Syrian refugees of reproductive age (15-49 years) living in Sanliurfa province. METHODOLOGY: A cross-sectional study was conducted in different districts of Sanliurfa. A total of 460 households were selected using the probability sampling method. One married female Syrian refugee aged between 15 and 49 years, was chosen in each household, leading to a sample size of 410 female Syrian refugees. The seropositivity of T. gondii, CMV, and rub IgM and IgG in blood samples were analyzed using enzyme immunoassays (Abbott Architect, Illinois, USA). RESULTS: The seropositivity rates of T. gondii, CMV, and rubella IgM and IgG were 4.4% and 59.8%; 3.9%; and 99%; and 1.9%, and 99.5%, respectively. CONCLUSIONS: A screening program should be implemented for T. gondii, CMV, and rub infections for Syrian refugees. Seronegative women should be vaccinated against rub and educated about the transmission and preventive routes of toxoplasmosis and CMV infection.
Sujet(s)
Infections à cytomégalovirus , Réfugiés , Rubéole , Toxoplasmose , Humains , Femelle , Réfugiés/statistiques et données numériques , Adulte , Études séroépidémiologiques , Toxoplasmose/épidémiologie , Adolescent , Jeune adulte , Rubéole/épidémiologie , Syrie/épidémiologie , Syrie/ethnologie , Adulte d'âge moyen , Études transversales , Infections à cytomégalovirus/épidémiologie , Turquie/épidémiologie , Toxoplasma/immunologie , Anticorps antiviraux/sang , Cytomegalovirus/immunologie , Cytomegalovirus/isolement et purification , Immunoglobuline M/sangRÉSUMÉ
End-stage renal disease (ESRD) patients are considered immunocompromised, putting them at high risk for infections, including cytomegalovirus (CMV). CMV can affect hematological parameters, causing further complications in ESRD patients. This study intended to determine the seropositivity of CMV infection in hemodialysis patients and its effect on different blood parameters in ESRD patients to help decrease the overall dialysis associated morbidity and mortality. Blood samples were collected from 45 ESRD patients and 45 controls. A complete blood count was performed using an automated cell counter. CMV-specific IgM and IgG levels were measured using immunochemistry testing. The seropositivity for CMV-IgG was 42.2% in ESRD patients which was significantly higher than in control group (22.2%) (p=0.042). The seropositivity for CMV-IgM was 6.7% in ESRD patients with no difference with the control group (4.4%). The prevalence of anemia was significantly higher in CMV seropositive (77.3%) compared to CMV seronegative (47.8%) ESRD patients. Other studied blood parameters were not different between CMV seronegative and seropositive ESRD patients. In conclusion, CMV infection is a significant concern for dialysis patients and can affect hematological parameters, leading to further complications. Early detection and treatment of CMV infection and monitoring of CMV IgM and IgG levels are critical to prevent further complications and improve clinical outcomes.
Sujet(s)
Anticorps antiviraux , Infections à cytomégalovirus , Cytomegalovirus , Immunoglobuline G , Immunoglobuline M , Défaillance rénale chronique , Dialyse rénale , Humains , Dialyse rénale/effets indésirables , Infections à cytomégalovirus/sang , Infections à cytomégalovirus/immunologie , Infections à cytomégalovirus/épidémiologie , Femelle , Mâle , Cytomegalovirus/immunologie , Défaillance rénale chronique/thérapie , Défaillance rénale chronique/sang , Défaillance rénale chronique/complications , Défaillance rénale chronique/immunologie , Adulte d'âge moyen , Immunoglobuline M/sang , Anticorps antiviraux/sang , Immunoglobuline G/sang , Adulte , Anémie/sang , Anémie/immunologieRÉSUMÉ
Introduction. At the end of 2019 and the year before, there was a significant spread of measles in the World Health Organization (WHO) European Region.Gap statement. Among the countries that reported, a measles outbreak was Bosnia and Herzegovina (BiH).Aim. To describe the measles outbreak in BiH (an entity of the Federation of BiH, FBiH) in 2019.Methodology. Confirmatory IgM serology, measles nucleic acid detection by real-time RT-PCR and virus genotyping were done in the WHO-accredited laboratory for measles and rubella at the Clinical Center of the University of Sarajevo, Unit for Clinical Microbiology. Genotype was determined in all measles-RNA-positive cases by sequence analysis of the 450 nt fragment coding the C-terminal of measles virus nucleoprotein (N).Results. From 1 January to 31 December 2019, 1332 measles cases were reported, with the peak observed in April 2019 (413/1332, 31.01â%). Sarajevo Canton had the highest incidence, number of cases and percentage (206.4; 868/1332; 65.17â%) of measles cases. Around four-fifths of infected persons were unvaccinated (1086/1332, 81.53â%), while 4.58â% of the patients (61/1332) were immunized with one dose of measles-containing vaccine. The highest proportion of cases was found in children 0-6 years of age (738/1332, 55.41â%). Measles IgM positivity was determined in 75.88â% (346/456), while virus RNA was detected in 82.46â% (47/57) of the swab samples. All measles virus sequences belonged to genotype B3. SNP (position 216: C=>T) was detected in 1 of the 40 sequences obtained during this outbreak.Conclusion. Due to suboptimal immunization coverage, BiH belongs to countries at a high risk for measles outbreaks. Post-COVID-19 (coronavirus disease 2019) pandemic, targeted and tailored strategies are required to ensure routine vaccination demand and acceptance and broad partner and stakeholder group participation.
Sujet(s)
COVID-19 , Épidémies de maladies , Génotype , Virus de la rougeole , Rougeole , Humains , Rougeole/épidémiologie , Rougeole/virologie , Rougeole/prévention et contrôle , Virus de la rougeole/génétique , Virus de la rougeole/isolement et purification , Virus de la rougeole/classification , Virus de la rougeole/immunologie , Enfant , Mâle , Adulte , Enfant d'âge préscolaire , Adolescent , Femelle , Jeune adulte , Nourrisson , COVID-19/épidémiologie , COVID-19/prévention et contrôle , Bosnie-et-Herzégovine/épidémiologie , Adulte d'âge moyen , Immunoglobuline M/sang , ARN viral/génétique , SARS-CoV-2/génétique , SARS-CoV-2/immunologie , SARS-CoV-2/isolement et purification , Vaccin contre la rougeole/administration et posologie , Anticorps antiviraux/sangRÉSUMÉ
BACKGROUND: The indigenous population located in the central region of Brazil, is the second largest in terms of population size in the country. The Indigenous Reserve of Dourados has risk factors that increase the vulnerability of the indigenous population to infectious diseases, especially Human alphaherpesvirus (HSV-1), a neglected disease with high prevalence in priority populations in developing countries. The virus can also cause many more severe diseases, including widespread neonatal infections, herpetic keratitis, and herpes encephalitis, which can be fatal if left untreated. We estimated the prevalence of anti-HSV-1 antibodies and correlated it with the demographic and behavioral characteristics of the Indigenous population of the Jaguapirú and Bororó villages (Dourados, Mato Grosso do Sul (MS), Brazil). METHODS: Our approach was cross-sectional. From March 2017 to November 2018. Using anti-HSV-1 (Gg1) IgM and anti-HSV-1 (gG1) IgG Euroimmun and the detection and quantification of HSV-1 viral load in plasma samples, through real-time PCR. The maps were constructed using QGIS and the statistical analyses using R Studio software. RESULTS: A total of 1138 individuals (> 18 years old) were enrolled. The prevalence of anti-HSV-1 IgM and IgG were 20% and 97.5%, respectively. The prevalence of anti-HSV-1 antibodies for IgG was higher in both sexes. Anti-HSV-1 IgM antibodies were present in 17.1%, 21.2%, 12.5%, and 22% of the participants with urinary problems, genital wounds, genital warts, and urethral discharge, respectively. Real-time PCR was used for confirmatory testing; HSV-1 DNA was detected in 25.6% (54/211) of anti-HSV1 IgM-positive samples. Viral loads ranged from 5.99E + 02 to 3.36E + 13. CONCLUSIONS: The seroprevalence of HSV-1 IgM and detection of HSV-1 DNA in the Indigenous population confirmed high silent prevalence. Furthermore, the seroprevalence of HSV-1 in the Indigenous population was higher than that reported in the general adult Brazilian population. Various socioeconomic factors, drug use, and health and sexual behaviors could contribute to the facilitation of HSV-1 transmission in the Indigenous population. Our results may help develop culturally appropriate intervention programs that eliminate health access barriers and improve the implementation of public health policies aimed at promoting information regarding the prevention, treatment, and control of HSV-1 infection in Brazilian Indigenous populations.
Sujet(s)
Anticorps antiviraux , Herpès , Adolescent , Adulte , Sujet âgé , Enfant , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Anticorps antiviraux/sang , Brésil/épidémiologie , Études transversales , Herpès/épidémiologie , Herpès/virologie , Herpèsvirus humain de type 1/immunologie , Herpèsvirus humain de type 1/génétique , Immunoglobuline G/sang , Immunoglobuline M/sang , Indien Amérique Sud/statistiques et données numériques , Prévalence , Charge viraleRÉSUMÉ
BACKGROUND: Epidemiological data on seasonal coronaviruses (sCoVs) may provide insight on transmission patterns and demographic factors that favor coronaviruses (CoVs) with greater disease severity. This study describes the incidence of CoVs in several high-risk groups in Ottawa, Canada, from October 2020 to March 2022. METHODS: Serological assays quantified IgG and IgM antibodies to SARS-CoV-2, HCoV-OC43, HCoV-NL63, HCoV-HKU1, and HCoV-229E. Incident infections were compared between four population groups: individuals exposed to children, transit users, immunocompromised, and controls. Associations between antibody prevalence indicative of natural infection and demographic variables were assessed using regression analyses. RESULTS: Transit users and those exposed to children were at no greater risk of infection compared to the control group. Fewer infections were detected in the immunocompromised group (p = .03). SARS-CoV-2 seroprevalence was greater in individuals with low income and within ethnic minorities. CONCLUSIONS: Our findings suggest that nonpharmaceutical interventions intended to reduce SAR-CoV-2 transmission protected populations at high risk of exposure. The re-emergence of sCoVs and other common respiratory viruses alongside SARS-CoV-2 may alter infection patterns and increase the risk in vulnerable populations.
Sujet(s)
COVID-19 , SARS-CoV-2 , Saisons , Humains , COVID-19/épidémiologie , COVID-19/transmission , COVID-19/immunologie , Incidence , Mâle , Femelle , SARS-CoV-2/immunologie , Enfant , Adulte , Adulte d'âge moyen , Adolescent , Anticorps antiviraux/sang , Enfant d'âge préscolaire , Études séroépidémiologiques , Jeune adulte , Sujet âgé , Facteurs de risque , Canada/épidémiologie , Nourrisson , Pandémies , Immunoglobuline G/sang , Infections à coronavirus/épidémiologie , Infections à coronavirus/transmission , Infections à coronavirus/immunologie , Immunoglobuline M/sangRÉSUMÉ
OBJECTIVES: Measles cases are increasing remarkably in our country as well as all over the world. In this study, it was aimed to examine the epidemiological and clinical characteristics of measles cases detected in our hospital, as well as the measles seroprevalence in our region. METHODS: A total of 7,452 individuals whose measles IgG and/or IgM antibodies were studied between December 2021 and March 2023 in the Medical Virology Laboratory in Basaksehir Çam and Sakura City Hospital were included in this retrospective study. Measles IgG and IgM antibodies were analysed by enzyme-linked immunosorbent assay. Demographic information, clinical symptoms and laboratory data of the participants were obtained from the hospital's electronic medical records. RESULTS: A total of 102 measles cases were identified between December 2021 and March 2023. Of these cases, 77 (75.5%) patients were ≤ 18 years old. Of the 73 measles cases with vaccination information, 90% were unvaccinated. The measles seroprevalence rate was 72.8%. The lowest seroprevalence rate (4.8%) among the age groups was found in 8-11-month-old babies, the highest cases rate (35.7%) was detected in this age group. It was determined that measles immunity increased with age (r = 0.276, p < 0.001) and was over 89.3% over the age of 30. CONCLUSIONS: Measles immunity is insufficient in our region and measles remains an important public health problem until the age of 18. The recent increase in measles cases in our country and around the world shows that current vaccination programmes need to be implemented more decisively and strictly.
Sujet(s)
Rougeole , Humains , Rougeole/épidémiologie , Rougeole/prévention et contrôle , Femelle , Mâle , Études rétrospectives , Nourrisson , Adolescent , Enfant , Enfant d'âge préscolaire , Turquie/épidémiologie , Études séroépidémiologiques , Adulte , Hôpitaux urbains/statistiques et données numériques , Jeune adulte , Anticorps antiviraux/sang , Immunoglobuline G/sang , Immunoglobuline M/sang , Vaccin contre la rougeole/administration et posologieRÉSUMÉ
The COVID-19 pandemic has highlighted the role of breastfeeding in providing passive immunity to infants via specific anti-SARS-CoV-2 antibodies in breast milk. We aimed to quantify these antibodies across different lactation stages and identify influencing factors. This prospective study involved mother-child dyads from Innsbruck University Hospital, Austria, with a positive maternal SARS-CoV-2 test during pregnancy or peripartum between 2020 and 2023. We collected breast milk samples at various lactation stages and analyzed anti-Spike S1 receptor-binding domain (S1RBD) immunoglobulins (Ig). Maternal and neonatal data were obtained from interviews and medical records. This study included 140 mothers and 144 neonates. Anti-S1RBD-IgA (72.0%), -IgG (86.0%), and -IgM (41.7%) were highly present in colostrum and decreased as milk matured. Mothers with natural infection and vaccination exhibited higher anti-S1RBD-IgA and -IgG titers in all milk stages. Mothers with moderate to severe infections had higher concentrations of anti-S1RBD-IgA and -IgG in transitional milk and higher anti-S1RBD-IgA and -IgM in mature milk compared to those with mild or asymptomatic infections. Variations in antibody responses were also observed with preterm birth and across different virus waves. This study demonstrates the dynamic nature of breast milk Ig and underscores the importance of breastfeeding during a pandemic.
Sujet(s)
Anticorps antiviraux , Allaitement naturel , COVID-19 , Lait humain , SARS-CoV-2 , Humains , Lait humain/immunologie , Femelle , COVID-19/immunologie , COVID-19/épidémiologie , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , SARS-CoV-2/immunologie , Adulte , Études prospectives , Nouveau-né , Grossesse , Immunoglobuline G/sang , Immunoglobuline G/immunologie , Lactation/immunologie , Autriche/épidémiologie , Immunoglobuline M/sang , Immunoglobuline M/immunologie , Glycoprotéine de spicule des coronavirus/immunologie , Immunoglobuline A/immunologie , Immunoglobuline A/sang , Colostrum/immunologie , Immunité acquise d'origine maternelleRÉSUMÉ
BACKGROUND: The objective of this study was to investigate the clinical relevance of anti-prothrombin antibodies (aPT) and anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in relation to pregnancy outcomes and coagulation parameters, as well as immune markers. METHODS: We retrospectively analyzed 477 pregnant women with experienced at least one spontaneous miscarriage who were tested for aPT and aPS/PT antibodies, and compared their clinical characteristics, coagulation indicators, immune biomarkers, and pregnancy outcomes to assess the diagnostic accuracy of these antibodies. RESULTS: We found that the aPT IgG and the aPS/PT IgM were independently associated with increased risk of pregnancy loss, with odds ratios (ORs) of 1.055 (95% confidence interval [CI]: 1.009-1.103, p = 0.017) and 1.041 (95% CI: 1.015-1.067, p = 0.002), respectively. Moreover, we found that the aPS/PT IgM had a higher diagnostic performance than the aPT IgG, as indicated by the AUC of 0.663 and 0.593, respectively. The pregnancy loss rate was positively correlated with the level of aPS/PT IgM, while the aPT IgG is not. We also found that in the pregnancy loss group, aPT IgG showed negative correlations with prothrombin time (PT); aPS/PT IgM showed positive correlations with aPS/PT IgG. However, none of aPT IgG, aPT IgM, aPS/PT IgM, or aPS/PT IgG was related to other adverse pregnancy outcomes, such as preterm delivery, fetal growth restriction (FGR), or preeclampsia (PE). CONCLUSION: Our findings suggest that aPT IgG and aPS/PT IgM are independent risk factors for pregnancy loss, especially aPS/PT IgM, which has a positive linear correlation with pregnancy loss.